Hematology /Oncology Section Bibliography

Summary | Fellowship Goals & Objectives | Fellowship & Curriculum Description |
Faculty | Annual Reports | Bibliography | Applicant Requirements | Application Process
Housestaff Information | Center Tour | about U of A | about Tucson & Arizona

Hematology/Oncology 2004

(1) Book
(4) Web Pages
(14) Book Chapters
(29) Presentations
(76) Journal Articles
( 75) Meeting Abstracts
(11) Other Publications

Bishop, Maria C CEPEC - Comprehensive Education in Palliative/End of Life Care < www.cepec.arizona.edu >

Lopez, Ana Maria Arizona Cancer Center Breast cancer site http://www.azcc.arizona.edu/

Lopez, Ana Maria Arizona Telemedicine Program (APT) site http://www.telemedicine.arizona.edu

 

(1) Book
(scholarly books and monographs, authored or edited, conference proceedings)

Alberts David S and Hess, LM (Eds) The Only Proven Cure for Cancer: Prevention, Springer-Verlag, in press, 2004 .

(14) Chapters
(chapters in scholarly books and monographs)

Mahadevan D, Garewal, HS . Chronic Lymphocytic Leukemia , American College of Physicians PIER Project, 2004.

Alberts DS , Barakat R, Benbrook D, Boggess J, Brewer M, Brinton L, Castle P, Daly M, Davanipour Z, Garcia FA, Hess L, Keleghan J, Lu K, Method MM, Minasian L, Muller C, Mutter G, Rader J, Rodriguez G, Sobel G, Walker J: Prevention of Gynecologic Malignancies. In: Gynecologic Cancer: Controversies in Management , Gershenson, Gore, McGuire, Quinn, Thomas (eds.). Academic Press: Philadelphia , 2004

Stratton MS, Ahmann FR: Molecular Mechanisms of Selenium and Prostate Cancer Chemoprevention; page 31 - 51. Nutritional Biotechnology in the Fed and Food Industry ; Nottingham Press 2003.

(14) Chapters

Stratton MS, Stratton SP , Ranger-Moore J, Einspahr JG , Bowden GT, Alberts DS : Strategies in skin cancer chemoprevention . In: Cancer Chemoprevention Volume 2: Strategies for Chemoprevention , Kelloff GJ (ed.). In press, 2004.

Stratton MS, Stratton SP , Dionne SO, Thompson P, Jongewaard IN, Hakim I, Dilley T, Garland L , Ranger-Moore J, Alberts DS : Treatment of carcinogenesis. In: Principles of Molecular Oncology, 2 nd

Edition , Bronchud MH, Foote MA, Giaccone G. Olopade O, Workman P (eds). Humana Press: Totowa , NJ , pp 607-673, 2004.

Alberts DS , Hess LM, Von Hoff DD, Dorr RT. Pharmacology and Therapeutics in Gynecologic Cancer . In: Principles and Practice of Gynecologic Oncology , Hoskins, Perez, Young, Barakat, Markman, Randall (Eds). 4 th Edition, Lippincott, Williams and Wilkins: Philadelphia , 2004.

Lake D , Briggs A , Akporiaye E; Immunopharmacology ; Chapter 56; 959-86; Basic and Clinical Pharmacology ; revised 2004; The McGraw-Hill Companies

AT Stopeck and D Fuchs. Venous thromboembolic disease . In: Current Care of Women : Diagnosis and Treatment. Lemcke, Pattison, Marshall, Cowley (eds), Lange Medical Books/ McGraw-Hill , New York , 345-367, 2004.

Garland L , Eisenberg M, Powers P. Cancer of the Lung , in Manetta, A (ed): Cancer Prevention and Early Diagnosis in Women . Philadelphia , Mosby; 2004.

Hakim I, Garland L . Lung Cancer Prevention . In Alberts, Hess (Eds) The Only Proven Cancer Cure-Prevention . Springer-Verlag, 2004. (in press).

Stratton MS, Stratton SP , Dionne SO, Jongewaard IN, Thompson P, GARLAND L , Hakim I, Ranger-Moore J, Alberts DS . Treatment of Carcinogenesis , in Foote, M (ed): Principles of Molecular Oncology ; 2nd Edition. Humana Press , 2004.

Coe K, Lopez AM , Hess LM. Ovarian Cancer Prevention , Fundamentals of Cancer Prevention . Alberts, DS , Hess, LM (Eds.) Springer-Verlag, New York , NY Submitted.

Thompson PA, Lopez AM . Breast Cancer Prevention , Fundamentals of Cancer Prevention . Alberts, DS, Hess, LM (Eds.) Springer-Verlag, New York , NY Submitted

Weinstein RS, Barker G, Beiner S, Holcomb M, Krupinski EA, Lopez AM , Hughes, A, McNeely, RA. Policy and the Origins of the Arizona Statewide Telemedicine Program . Understanding Health Communication Technologies . Whitten P, Cook D (Eds.) Jossey-Bass, San Francisco , CA 2004

  (76) Journal Articles
(refereed/peer-reviewed journal articles, published on in accepted final form, conference papers)

Ahmann FR : Prostate Cancer Screening - How Much Evidence is Enough? Arizona Geriatric Society Journal 9:1:31-32 2004

Ahmann FR : Prostate Cancer Screening - How Much Evidence is Enough? Arizona Geriatric Society Journal 9:1:31-32 2004

Chow HH, Anavy N, Salazar D, Frank DH , Alberts DS : Determination of celecoxib in human plasma using solid-phase extraction and high-performance liquid chromatography. J Pharm Biomed Anal 34:167-174, 2004.

Harris RB, Alberts DS : Strategies for skin cancer prevention. Int J Dermatol, in press, 2004.

Frank DH , Roe DJ, Chow HH, Guillen JM, Choquette K, Gracie D, Francis J, Fish A, Alberts DS : Effects of a high-selenium yeast supplement on celecoxib plasma levels: A randomized phase II trial. Cancer Epidemiol Biomarkers Prev 13:299-303, 2004.

Jacobs ET, Giuliano AR, Roe DJ, Guillen-Rodriguez JM, Hartz VL, Whitacre RC, Alberts DS , Martinez ME: Dietary change in an intervention trial of wheat bran fiber and colorectal adenoma recurrence. Ann Epidemiol 14(4):280-286, 2004.

Alberts DS , Jiang C, Liu PY, Wilczynski S, Markman M, Rothenberg ML: Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Oncol 14:224-228, 2004.

Alberts D , Ranger-Moore J, Einspahr J , Saboda K, Bozzo P, Liu Y, Xu XC, Lotan R, Warneke J, Salasche S, Stratton S , Levine N, Goldman R, Islas M, Duckett L, Thompson D, Bartels P: Safety and efficacy of dose intensive oral vitamin A in subjects with sun-damaged skin. Clin Cancer Res 10:1875-1880, 2004.

Martinez ME , Henning S, Alberts DS : Folate and colorectal neoplasia: review of the literature and relationship between plasma and dietary markers of folate and adenoma recurrence. Am J Clin Nutr, 79:691-697, 2004.

Martinez ME , Reid M, Jiang R, Einspahr J, Alberts DS : Accuracy of self-reported smoking status and assessment of quit rate among participants in a chemoprevention trial. Prev Med 38:492-497, 2004.

Hess LM, Krutzsch MF, Guillen J, Chow HH, Einspahr J , Batta AK , Salen G, Reid ME, Earnest DL, Alberts DS : Results of a phase I multiple-dose clinical study of ursodeoxycholic acid (UDCA). Cancer Epidemiol Biomarkers Prev 13(5):861-867, 2004.

Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB , Humphrey S, Albers DS : Effects of a superpotent melanotropic peptide in combination with solar ultraviolet radiation on tanning of the skin in human volunteers. Arch Dermatol 140:827-835, 2004.

homson CA , Rock CL, Giuliano AR , Newton TR, Cui H, Reid PM, Green TL, Alberts DS : Longitudinal changes in body weight and body composition among women previously treated for breast cancer consuming a high-vegetable, fruit and fiber, low-fat diet. Eur J Nutr, Online First, pgs 1-8, March 5, 2004 .

tiff PJ, Shpall EJ, Liu PY, Wilczynski SP, Callander NS, Scudder SA, Jazieh AR , Samlowski W, McCoy J, Alberts DS : Randomized phase II trial of two high dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: A Southwest Oncology Group study. Gynecol Oncol 94(1):98-106, 2004.

Martinez ME , Reid M, Jiang R, Einspahr J, Alberts DS : Accuracy of self-reported smoking status among participants in a chemoprevention trial. Preven Med, 38:492-497, 2004.

Ranger-Moore J, Bartels P, Thompson D, Bozzo P, Einspahr J, Liu Y, Saboda K, Duckett L, Alberts DS : Karyometric analysis of actinic damage in unexposed and sun-exposed skin, and in actinic keratoses in untreated individuals. Analytical and Quantitative Cytol and Histol 26:155-165, 2004.

Chen Z, Stini WA, Marshall JR, Martinez ME, Guillen-Rodriguez JM, Roe D, Alberts DS : Wheat bran fiber supplementation and bone loss among older people. Nutrition 20:747-751, 2004.

Prentice RL, Willett WC, Greenwald P, Alberts D , Bernstein L, Boyd NF, Byers T, Clinton SK, Fraser G, Freedman L, Hunter D, Kipnis V, Kolonel LN, Kristal BS, Kristal A, Lampe JW, McTiernan A, Milner J, Patterson RE, Potter J, Riboli E, Schatzkin A, Yates A and Yetley E: Nutrition, physical activity and chronic disease prevention: Research strategies and recommendations. J Natl Cancer Inst, 96(17):1276-1287, 2004.

Smith HO, Jiang C, Weiss GR, Hallum AV III, Liu PY, Robinson WR III, Pui CC, Scudder SA, Markman M, Alberts DS : Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: A Southwest Oncology Group Study. Int J Gynecol Oncol, in press, 2004.

Lavey RS, Liu PY, Greer BE, Robinson WR, Pui CC, Wynn RB, Conrad ME, Jiang C, Markman M, Alberts DS : Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol, 95:145-151, 2004.

Brewer MA, Ranger-Moore J, Alberts DS , Greene MH, Liu Y, Bartels PH, Baruch AC: Exploratory study of ovarian intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev, 2004.

Ranger-Moore J, Bartels P, Thompson D, Bozzo P, Einspahr J , Liu Y, Saboda K, Duckett L, Alberts DS : Karyometric analysis of actinic damage in unexposed and sun-exposed skin, and in actinic keratoses in untreated individuals. Analytical and Quantitative Cytology and Histology, 26(No.3):155-165, 2004.

Garcia F, Ranger-Moore J, Barker B, Davis J, Brewer M, Yemane J, Hatch K, Alberts DS , Bartels HG, Bartels PH: Karyometric image analysis for intraepithelial and invasive cervical lesions. Analytical and Quantitative Cytology and Histology, 26(3):155-165, 2004.

Brewer M, Ranger-Moore J, Greene MH, Alberts DS , Liu Y, Bartels H, Bartels PH: Preneoplastic changes in ovarian tissues. Analytical and Quantitative Cytology and Histology, Aug. 26(4):207-216, 2004.

Jacobs ET, Jiang R, Alberts DS , Greenberg ER, Gunter EW, Karagas MR, Lanza E, Ratnasinghe L, Reid ME, Schatzkin A, Smith-Warner SA, Wallace K, Martinez ME : Selenium and colorectal adenoma: Results of a pooled analysis. J Natl Cancer Inst 96(22):1669-1675, 2004.

Rothenberg ML, Liu PY, Wilczynski S, Hahhas WA , Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS : Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group Study. Gynecologic Oncology, in press, 2004.

Thigpen JT, Aghajanian CA , Alberts DS , Campos SM, Gordon AN, Markman M, McMeekin S, Monk BJ, Rose PG: Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecologic Oncol, in press, 2004.

J ordan BF, Runquisht M, Raghunand N, Gillies RJ, Tate WR, Powis G, Baker AF . The thioredoxin-1 inhibitor PX-12 decreases vascular permeability as monitored by dynamic contrast enhanced MRI, comparison with VEGF production in xenograft tumors. In Press, Clinical Cancer Research, 2004.

Jordan, BF, Runquisht M, Raghunand N, Baker AF , Powis G, Gillies RJ. Imaging th effects of HIF1a inhibition by diffusion and dynamic enhanced MRI. In Press, Neoplasia, 2004.

G illet EJ, IHle N, Baker, AF , Gard JM, Stamper C, Williams R, Coon A, Mahadevan D , George BL, Kirkpatrick L, Powis G. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncology Research, 14;513-527, 2004.

Dayani P, Bishop MC , Black K, Zeltzer P, "Desferoxamine (DFO) - Mediated Iron Chelation Rational For A Novel Approach To Therapy For Brain Cancer." Journal of Neuro-Oncology. Vol 67 (3): 367-377, May 2004.

Bishop MC , Taylor AM, Ahner H, Olson-Garewal K, Rein J, Reiser S, Garewal HS . Initial Phases of Development of a Multidisciplinary, Culturally Competent Cancer and End-of-Life Curriculum for Medical Students. Journal of Cancer Education, Vol 19, No. 3 Fall 2004.

Cranmer et al. 2004. Cancer Immurol. Immunotherpay 53(4):275-306.

Zhilina ZV, Ziemba AJ, Trent JO, Reed MW, Gorn V, Zhou Q, Duan W, Hurley L, Ebbinghaus SW . Synthesis and evaluation of a triplex-forming oligonucleotide-pyrrolobenzodiazepine conjugate. Bioconjug Chem . 15:1182-92, 2004

Dvorakova K, Payne CM, Ramsey L, Holubec H, Sampliner R, Domingrez J, Dvorak B, Bernstein H, Bernstein C, Prasad A, Fass R, Cui H, Garewal HS. Increased expression and secretion of Interleukin-6 in patients with Barrett's esophagus. Clinical Cancer Research, 10:2020 - 2028; 2004

Bernstein H, Payne CM, Kunke K, Crowley-Weber C, Waltmire C, Dvorakova K. Holubec H, Bernstein C, Vaillancourt R, Garewal HS . A proteomic study of resistance to deoxycholate-induced apoptosis. Carcinogenesis, in press.

Lieberman DA, Prindiville S, Weiss DG, Willett W and the VA Cooperative Study 380 Group. H. Garewal, Member and Author . Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. J. Am. Medical Assoc., 290:2959 - 2967, 2004.

Ahn SH, Garewal HS . Low erythropoietin level can cause anemia in patients without advanced renal failure. Am Journal Medicine, 116: 280 - 281, 2004.

Bernstein H, Bernstein C, Payne C, Dvorakova K, Garewal H . Bile acids as carcinogens in human gastrointestinal cancers. Reviews in Mutation Research, in Press 2004.

Dvorakova K, Garewal HS . Can the effect of acid-suppressive treatment on unconjugated bile acids favor mucosal damage? In Duodeno-Gastric Reflux, ed. R. Giuli, Proceedings of 8 th OESO Conference, 2004.

Dvorakova K, Garewal HS . Bile acids, cytokines and apoptosis in Barrett's esophagus. In Duodeno-Gastric Reflux, ed. R. Giuli, Proceedings of 8 th OESO Conference, 2004.

Schrag D, Garewal H , Burstein H, Samson D, Von Hoff D, Somerfield M (for the ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays). American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J. Clinical Oncology 22:3631-3638, 2004.

Bernstein H, Bernstein C, Payne C, Dvorakova K, Garewal H . Recent molecular evidence illuminates the decades-long debate on the role of dietary fat in colon carcinogenesis. Journal of Cancer Integrative Medicine, in Press, 2004.

Dvorakova K, Payne C, Ramsey L, Bernstein H, Holubec H, Chavarria M, Bernstein C, Sampliner R, Riley C, Prasad A, Garewal H . Apoptosis resistance in Barrett's esophagus. Ex Vivo Assay of Live Stressed Tissues. Am Journal Gastroenterology, in Press.

Jacobsen P, Garland L , Booth-Jones M, Donovan KA, Thors CL, Winters E, Grendys E. Relationship of Hemoglobin Levels to Fatigue and Cognitive Functioning Among Cancer Patients Receiving Chemotherapy. Journal of Pain and Symptom Management 2004;28:7-18.

Chow, H-H. S., N. Anavy , D. Salazar, Frank DH , Alberts DS . 2004. Determinantion of celecoxib in human plasma using solid-phase extraction and high-performance liquid chromatography.Journal of Pharmaceutical and Biomedical Analysis, (34), 167-174.

Frank, DH , Roe DJ, H-H. S. Chow, Guillen JM, Choquette K, Gracie D, Childs J, Fish A, Alberts DS . 2004. Effects of a High-Selenium Yeast Supplement on Celecoxib Plasma Levels: A Randomized Phase II trial.Cancer Epidemiology Biomarkers and Prevention, 13, (2), 299-303

Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. T.H. Landowski , C.J. Megli, K.D. Nullmeyer, R.M. Lynch, and R.T. Dorr. Accepted for publication, Cancer Research.

Avery D , Lopez AM . Increasing Access to Care via Tele-Health: The Arizona Experience. Journal of Ambulatory Care Management 28:1, pp 16-23, 2004

Zhao C, Michael, M, Bassford TL, Pettinger M, Ritenbough C, Lopez AM , Barad, DH, Gass M, LeBoff, MS. Fracture Risk among Breast Cancer Survivors - Results from the Women's Health Initiative Observational Study. Submitted Fall 2004.

Avery D , Lopez AM . Increasing Access to Care via Tele-Health: The Arizona Experience. Submitted Summer 2004.

Badger T, Segrin C, Meek P, Lopez AM , Bonham E, Sieger A. Telephone Interpersonal Counseling with Women with Breast Cancer: Symptom Management and Quality of Life. Scheduled for publication March 2005.

Cruz M, Krupinski EA, Lopez AM, Weinstein RS. The University of Arizona Telepsychiatry Program: The First Five Years. Submitted Spring 2004.

Badger T, Segrin C, Meek P, Lopez AM , Bonham E. A Case Study of Telephone Interpersonal Counseling for Women With Breast Cancer and Their Partners. Oncology Nursing Forum 31:5, 2004.

Krupinski EA, Barker G, Lopez AM , Weinstein RS. An Analysis of Unsuccessful Teleconsultations. Journal of Telemedicine and Telecare 10:6-10, 2004.\

D Mahadevan, J DiMento , KD Croce, C Riley, B George, D Fuchs, T Mathews, C Wilson and M Lobell , Transcriptosome and Serum Cytokine Profiling of an Atypical case of MDS with Progression to AML, being reviewed by Leukemia Research for publication.

A List, S Kurtin , D Roe, A Buresh , D Mahadevan, D Fuchs, L Rimsza, R Heaton, R Knight, J Zeldis (Accepted to New England Journal of Medicine, Dec 2004). Efficacy and Safety of Lenalidomide for the Treatment of Refractory Anemia in Patients with Myelodysplastic Syndrome.

Meuillet E, Ihle N, Baker A, Gard J, Stamper C, Williams R, Coon A, Mahadevan D , George B, Kirkpatrick L, and Powis G. Oncology Research. 2004, 14: 1-15 In vivo Molecular pharmacology and Antitumor activity of the Targeted Akt inhibitor PX-316.

Meuillet E, Mahadevan D , Berggren M, Coon A, and Powis G. Arch Biochem Biophys . 2004 Sep 15;429(2):123-33. Thioredoxin-1 binds to the C2 domain of PTEN's lipid phosphatase activity and membrane binding: A mechanism for the functional loss of PTEN's tumor suppressor activity .

Mahadevan D and List A. Blood. 2004 Oct 1;104(7):1940-51. Targeting the Multidrug Resistance1 Transporter in AML: Molecular Regulation and Therapeutic Strategies.

Mahadevan D , List AF, Tate W, Glinsmann-Gibson BJ, Baker A. The immunomodulatory Thalidomide Analog CC5013 is a potent receptor tyrosine kinase (RTK) inhibitor that abolishes vascular endothelial growth factor (VEGF) trophic response in malignant myeloid progenitors. Leukemia Research Clinical and Laboratory Studies ; 27(1):S108, May 2003.

Meuillet E, Mahadevan D , Vankayalapati H, Berggren M, Williams R, Coon A, Kozikowski A, Powis G. Specific Inhibition of the AKT1 Pleckstrin Homology Domain by D-3-Deoxy-Phosphatidyl-myo-Inositol Analogues. Mol Cancer Ther ; 2:389-399, April 2003.

Vankayalapati H, Rojanala S, Saldanha J, Munoz R, Bearss D, Hurley L, Von Hoff DD and Mahadevan D . Targeting Aurora Kinase 2 in Oncogenesis: A Structural Bioinformatics Approach to Target Validation and Rational Drug Design. Mol Cancer Ther, 3:283-294; March 2003.

Mahadevan D , Bearss D and Vankayalapati H. Current Medicinal Chemistry, Structure Based Design of Novel Anti-Cancer Agents Targeting Aurora Kinase. Curr Med Chem Anti-Cancer Agents , 3:25 -34, 2003.

Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Greiner TC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E,Fuchs DA,  Spier CM, Fisher RI, Delabe J, Rosenwald A, Staudt LM, Grogan TM.  Loss of MHC Class II Gene and Protein Expression in Diffuse Large B Cell Lymphoma is Related to Decreased Tumor Immunosurveillance and Poor Patient Survival Irrespective of other Prognostic Factors: A Follow-up Study from the Leukemia Lymphoma Molecular Profiling Project. Blood 103(11): 4251-4258, 2004

Hehn ST, Miller TP . What is the treatment of Choice for Advanced stage Hodgkin Lymphoma: ABVD, Stanford V, or BEACOPP? Current Hematology Reports 3:17 -26, 2004.

Hehn ST, Gorgan TM, Miller TP . Utility of Fine-Needle Aspiration as a Diagnostic Technique in Lymphoma. J Clin Oncol 22:3046-3052, 2004

Dave SD, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM , Grogan TM, Miller TP , LeBlanc M, et al. The Lymphoma/Leukemia Molecular Profiling Project. Length of Survival Following the Diagnosis of Follicular Lymphoma is Predicted by Molecular Features of Non-Malignant Tumor-Infiltrating Immune Cells. New England Journal of Medicine 2004.

Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP , Moore, JO, Leonard JP, Gordon LI, Sweetenham J, Alkzweny B, Finucane DM, Leigh BR. A Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory, Follicular Lymphoma. Journal Clinical Oncology (submitted) 2004

Zangari M, Anaissie E, Stopeck A , Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res., 10:88-95, January 2004.

O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louise SG, Hong W , Stopeck AT , Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, oh FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res., 28:679-689, July 2004.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A , Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med, 351:781-791, August 2004.

Theilmann R, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, Gillies R, Stopeck A . Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia, 6(6): 831-837, December 2004

Mustacich, D., Wagner, A., Williams, R., Bair, W., Barbercheck, L., Stratton, S.P ., Bhattacharyya, A.K., and Powis, G. Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse. Carcinogenesis , 25:1983-1989, 2004.

Gupta, A., Stratton, S.P., and Myrdal, P.B. An HPLC method for quantitation of perillyl alcohol in a topical pharmaceutical cream formulation. J.Pharm.Biomed.Anal. (in press) , 2004.

(75) Meeting Abstracts
(conference paper abstracts and poster abstracts)

R anger-Moore J, Bartels P, Einspahr J, Alberts DS , Frank DH , Brentnall T, and Lance P. The Utility of Karyometric Analysis for Detection of Colorectal Cancer and Prediction of Recurrent Adenomas. American Gastroenterology Society Annual Meeting. New Orleans , LA , July 2004

Im SS, Monk BJ, Wang J, Stock RJ, Peters WA 3rd, Liu PY, Barrett RJ 2nd, Berek JS, Souhami L, Grisby P, Gordon W, Alberts DS : Rethinking the use of chemotherapy and radiation after radical hysterectomy: A clinical-pathologic analysis of SWOG 8797/GOG 109. Proc. Society of Gynecologic Oncologists (SGO) 92:396, 2004. Annual Meeting on Women's Cancer, San Diego , CA , February 7-11, 2004 .

Marshall JR, Sakr W, Wood D, Alberts D , Tangen C, Faulkner J, Parker F, Lippman S, Thompson I, Greenwald P, Minasian L, Lieberman R, Crawford D: Selenium-based prostate cancer chemoprevention for those with prostatic intraepithelial neoplasia. AACR Frontiers in Cancer Prevention, Seattle , WA , October 16-19, 2004 , CEBP Suppl 13(11):73, 2004.

Alberts DS : Intraperitoneal therapy for stage III, optimally debulked ovarian cancer (Optimal OV CA): Isn't it about time to take the phase III trial data seriously? 10 th Biennial International Gynecologic Cancer Society Meeting, Edinburgh , Scotland , October 3-7, 2004 .

Brewer MA, Ranger-Moore J, Alberts DS , Hatch K, Thompson D, Liu Y, Davis J, Baruch A, Bartels PH: Exploratory study of ovarian intraepithelial neoplasia. Society of Gynecologic Oncologists (SGO) 2004 Annual Meeting on Women's Cancer, San Diego, CA, February 7-11, 2004.

Smith HO, Jiang C, Weiss GR, Hallum AV 3rd, Liu PY, Miller AM, Gandara DR, Markman M, Alberts DS : Tirapazamine plus cisplatin in advanced or recurrent squamous or adenosquamous carcinoma of the uterine cervix: A phase II study of the Southwest Oncology Group (SWOG). Society of Gynecologic Oncologists (SGO) 2004 Annual Meeting on Women's Cancer, San Diego, CA, February 7-11, 2004.

Krouse RS, Rial NS, Einspahr JG , Buckmeier JA, Ismail A, Bhattacharyya AK, Prasad A, Kepler CY, Pollock MR, Allen AN, Alberts DS : Candidate biomarkers in colorectal cancer progression. Society of Surgical Oncology (SSO) Meeting, New York , NY , March 18-21, 2004 .

Einspahr JG, Alberts DS , Bhattacharrya AK, Martinez ME, Wilkinson J, Issa JP, Buckmeier JA, Rashid A, Houlihan P, Lance MP, Hamilton SR: Ki-ras mutations and p53 overexpression in adenomas from a phase III trial of recurrence. AACR, Orlando , FL , March 27-31, 2004 .

Shen L, Kondo Y, Hernandez NS , Vilaythong J, Houlihan PS, Krouse RS, Prasad AR , Einspahr JG , Buckmeier J, Alberts DS , Hamilton SR, Issa JP: Epigenetic inactivation of MGMT defines a field defect in sporadic colorectal cancer. AACR, Orlando , FL , March 27-31, 2004 .

Ranger-Moore J, Bartels P, Einspahr J , Alberts D , Frank D , Brentnall T, Lance P: The utility of karyometric analysis for detection of colorectal cancer and prediction of recurrent adenomas. Digestive Disease Week, New Orleans , LA , May 15-20, 2004 .

Baruch AC, Davis JR, Brewer, MA, Ranger-Moore, J, Alberts, DS , Thompson D, Liu Y, Bartels, PH: Nuclear chromatin characteristics of surface epithelial and stromal cells in non-malignant and malignant ovaries. USCAP, 2004.

Larkey LK, Alberts DS , Lance, P, Goode DA: Strategies to improve regional colorectal cancer screening rates. Educational Conference on Cancer Prevention. Dead Sea , Israel , May 6-8, 2004 .

Martinez ME , Thompson P, Jacobs ET, Jiang R, Alberts DS : Insulin resistance syndrome, PPAR?, and overweight/obesity status among individuals with colorectal adenomatous polyps. Proc. AACR Frontiers in Cancer Prevention, Seattle , WA , October 16-19, 2004 , CEBP Suppl 13(11):176, 2004.

Alberts DS , Martinez E, Jacobs E, Einspahr J , Hamilton S, Issa J-P, Lance P: Large phase III clinical trials: The importance of secondary endpoint analyses. AACR Frontiers in Cancer Prevention, Seattle , WA , October 16-19, 2004 .

Redfern CH, Hart L, Srinvas S, Sall S, McCune D, Boyd T, Sandler AS , Sing AP, Siegal C, Ahmann FR : A Phase II Study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel in patients with hormone refractory prostate carcinoma. Abstract 704, Proc of ASCO 22:176, 2003.

Bishop MC , Results of 2 Phase I Studies of Intravenous Pelitroxol (AG2037), a Glycinamide Ribonucleotide Formyltransferase (GARFT) Inhibitor, in Patients with Solid Tumor. ASCO May 2004.

Initial Phases of Development of a Multidisciplinary, Culturally Competent Cancer and End-of-Life Curriculum for Medical Students. Bishop MC , Taylor AM, Ahner H, Olson-Garewal K, Rein J, Reiser S, Garewal HS . AACE Oct 2004.

Initial Phases of Development of a Multidisciplinary, Culturally Competent Cancer and End of Life Curriculum for Medical Students. Bishop MC , Taylor AM, Ahner H, Garewal HS , Jaskar D, Gores F, Koff N. 4th VA National Leadership Conference on Pain Management and End of Life Care. March 2005. Accepted

Kirkpatrick L, Dragovich T, Ramanathan R, Sharlow E, Chow S, Williams D, Himler R, Baker A , Egorin M. Results from Phase I studyof PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies. Proc. Amer. Assoc. Clin. Oncol. 23, 217, 2004.

Baker AF , Dragovich T , Tate WR, Kirkpatrick DL, Powis G. Pharmacodynamic proteomic studies of the thioredoxin-1 inhibitor PX-12 in mice an patients. American Association of Cancer Research Annual Meeting, Orlando , FL , 2004.

Baker AF , Bellamy W, Tate WR, Bair W, Glinsmann-Gibson B, Heaton R, List A. Suppressor of Cytokine Signaling-3 Proein (SOCS-3) is up-regulated in myelodysplastic syndrome. American Association of Cancer Research Annual Meeting, Orlando , FL , 2004.

Dragovich T , Ramanathan R, Sharlow E, Chow S, Williams D, Himler R, Baker A, Egorin M. Results from Phase I Study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2004 (abst #3089).

Dorr RT, Dragovich T , Hersh E, Patrick K. Phase I clinical trial of imoxen: A mitochondrial

thioloxidant. Proc Am Soc Clin Oncol 2004 ( abst #3181)

Porterfield BW , Dragovich T , Patnaik A, Rowinsky E, Huberman M, Clinebell T, Hamilton M, Zitelli

A, Nadler P, Wood D. Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma:

Results from a phase IB trial. Proc Am Soc Clin Oncol 2004 (abst #4110)

Dragovich T, Baker AF , Wendy R. Tate and . Pharmacodynamic and Proteomic Studies of the Thioredoxin-1 Inhibition: From Mice to Man. ASCO 2004 (abst.#293)

Ziemba AJ, Zhilina ZV, Krotova-Khan Y, Stankova L , Ebbinghaus SW . Targeting and regulation of the HER-2/neu promoter with a bis-peptide nucleic acid. Oligonucleotides (submitted on December 20, 2004 )

Ebbinghaus S , Rubin E, Hersh E , Cranmer LD , Bonate P, Fram RJ, Jekunen A, Weitman S, and Hammond L, A phase I study of the dolastatin-15 analog 1LX651 administered intravenously daily for five consecutive days every three weeks in patients with advanced solid tumors. J Clin Oncol (submitted on November 16, 2004 )

Martinez ME, Thompson P, Einspahr J , Hamilton S, Jacobs E, Alberts DS : Genetic variant in the peroxisome proliferators-activator receptor-gamma (PPAR?) gene as predictor of Ki-ras mutations in colorectal adenomas. NCI SPORE Meeting, Bethesda , MD 2004.

Martinez ME , Einspahr J , Jiang R, Swan S, Lance P, Alberts D : Ascertainment of colorectal polyp characteristics from medical records: Can data be captured with a high degree of accuracy? Proc. AACR Frontiers in Cancer Prevention, Seattle , WA , October 16-19, 2004 , CEBP Suppl 13(11):170, 2004.

Hess LM, Guillen J, Krutzsch M, Salen G, Batta A, Einspahr J , Alberts DS : A phase I multiple-dose safety and pharmacokinetic clinical study of ursodeoxycholic acid: Results of Task II. AACR Frontiers in Cancer Prevention, Seattle , WA , October 16-19, 2004 , CEBP Suppl 13(11):126, 2004.

Garland L , Rankin C, Scott K, Nagle R, Lobell M, Gandara D, Rivkin S, Atkins J, Samlowski W, Borden E. Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) In Patients with Malignant Pleural Mesothelioma (MPM). Proc ASCO, 2004.

Taylor CW, Walker P, Tang-Liu D, Joshi T, Gebremarian C, Jordan S, Yu Z, Von Hoff D, Garland L . A Phase I and Pharmacokinetic Study of HMN-214, a Novel Oral Polo-Like Kinase Inhibitor, in Patients with Advanced Solid Tumors. Proc ASCO, 2004.

A Phase I and Pharmacokinetic Study of HMN-214, a Novel Oral Polo-Like Kinase Inhibitor, in Patients with Advanced Solid Tumors. Von Hoff DD, Taylor C, Rubin S, Cohen J, Garland L . Proc ASCO, 2004.

Landowski TH , Megli CJ, Dorr RT, Dalton WS. Calcium-mediated mitochondrial perturbation is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. (Selected for poster discussion) AACR Annual Meeting (2004).

Shain KH, Kelsch D, Huang M, Alsina M, Jove R,. Landowski T , and Dalton WS. Integrin-mediated adhesion enhances IL-6 signaling through Stat3, ERK1/2, and Akt: Evidence for a network of intracellular crosstalk between integrins and cytokines in myeloma cells. AACR Annual Meeting (2004).

Dorr RT, Roman N, Raymond MA, Pourpak A, Landowski T . Imexon has antitumor activity against human pancreatic cancer. AACR Annual Meeting (2004).

Dorr RT , Roman N, Raymond MR, Landowski T , Hersh E. Imexon induces apoptosis in human pancreatic cancer cells by alteration of cellular redox status. Pancreatic Cancer 2004: Advances and Challenges, San Francisco , CA , (2004).

Escalante A, Landowski T , Dorr RT, Stratton S. Role of NF-?B in UV-B irradiated Immoratlized Keratinocytes post-treated with epigallocatechin-3-gallate. AACR Frontiers in Cancer Research, Seattle , WA , (2004).

Fukushima S, Landowski TH , Raymond MA, Roman N, Dorr RT. Imexon induces cell cycle arrest and apoptosis against human pancreatic cancer cell line (MiaPaCa-2) in vitro. AACR Cell Cycle and Cancer: Pathways and Therapies Ft. Lauderdale , FL (2004).

Baker LH, Demetri G, Medelson D, Rowinsky E, Knight R, Carlson D, Lobell M ; University of Michigan, Ann Arbor; Center for Sarcoma and Bone Oncology, Harvard, Boston, MA; University of Arizona, Arizona Cancer Center, Scottsdale, AZ; Cancer Research Center, San Antonio, TX; Abbott Laboratories, Abbott Park, IL, University of Arizona, Arizona Cancer Center, Tucson, AZ; A Randomized Phase 2 Study of Thrombospondin-Mimetic Peptide ABT-510 in Patients With Advanced Soft Tissue Sarcoma (STS) , Abstract Tracking # 05-AB-31760-ASCO

L. Garland , C. Randkin, K. Scott, R. Nagle, M. Lobell , D. Gandara, S. Rivkin, W. Samlowski, J. Atkins, E. Borden; Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: A Phase II Study of Oral EGFR Tyrosine Kinas Inhibitor OSI-774 (NSC-718781) In patients with Malignant Pleural Mesothelioma (MPM). Abstract, ASCO 40 th Annual Meeting, June 2004

K Trevor , L Tillman, S Myers, G Castro, C Wilson, T Mathews, K Coe, M Lobell ; Lyphocytic Infiltrates Associated with Aggressive Breast Cancers in Younger Native American Women. Poster , SPN Annual Meeting, July 2004

Kaemingk Kris, Reminger S, Kervick R, Venker C, Lopez AM , Krouse R, Dragovich T, Seeger J, Gordon M. Memory difficulties in Breast and Colon Cancer Survivors may be Related to Reduced Hippocampal Volume . Submitted to NCI/ACS Cancer Survivors Conference 2004.

Reminger SL, Kervick RB, Lopez AM, Dragovich T, Krouse RS, Kaemingk KL. Memory Performance in Cancer Survivors is Related to MRI Measures of Hippocampal Volume . Poster presented at the 1st Annual Meeting of the American Psychosocial Oncology Society, Orlando , FL. Psycho-Oncology, 13, S31, 2004.

Lopez, AM. Telecolposcopy: Data from a university tertiary care colposcopy clinic. Selected for presentation during the 132 nd APHA annual meeting, November 6-10, 2004 , Washington , DC .

Lopez AM et al. Telecolposcopy in a Tertiary Care Women's Clinic: A Pilot Study. Selected for publication in the ASCO Proceedings of the June 2004 meeting, New Orleans LA.

Lopez AM . Chemotherapy for Breast Cancer. Selected for presentation during the Womens Integrative Medicine Conference. June7, 2004, Tempe , AZ.

Lopez AM . HRT as a risk factor for breast cancer; current thoughts. Selected for presentation during the Womens Integrative Medicine Conference. June7, 2004, Tempe , AZ.

Lopez AM , Lazarus S, Contreras M, Eisendrath S. Changing the Medical School curricula to address Women's Health Education. The University of Arizona College of Medicine Experience . Poster presentation at the Graduate Symposium on Women in Higher Education. Association for Women Faculty. To be published in the Symposium Proceedings. University of Arizona , March 26, 2004 .

L opez AM , Avery D, Weinstein RS. Women's Health Care via Telemedicine . American Telemedicine Association 9 th Annual Meeting, May 2-5, 2004 . Telemedicine Journal and e-Health Vol 10, Supplement 1 pS-105 Abstract #P58, 2004.

Lopez AM , Garcia F, Hatch K, Byron J, Kurker SF, Guillen J, Major J, Lazarus S, Avery D, Weinstein

Rojanala S, Han H, Munoz RM, Vankayalapati H, Mahadevan D , Hurley LH, Von Hoff DD, and Bearss DJ. Aurora kinase-2, a potential molecular therapeutic target for pancreatic cancers. Proc Am Assoc Cancer Res , 43:665, 2002.

ASH 2004: Gene Expression Profiling of Peripheral T-cell Lymphoma (PTCL, NOS) and Comparison to Diffuse Large B-cell Lymphoma (DLBCL). D Mahadevan , C. Spier, K. Della Croce, S. Miller, B. George, C. Riley, S. Warner, T. M. Grogan and T. P. Miller. University of Arizona Cancer Center , Tucson , AZ , 85724 .

ASCO 2004 Phase I trial of gemcitabine and epirubicin in patients with solid malignancies. D. Mahadevan , L. Dreisbach, D. Williams, D. Pilkington, C. Gebremarium, E. Martin,n Y. Obregon, D. Von Hoff, Arizona Cancer Center, Tucson, AZ; Desert Hematology & Oncology, Rancho Mirage, CA

AACR 2004 Abstract: A Humanized Anti-CEACAM6 Monoclonal Antibody Targeting Pancreatic Adenocarcinoma demonstrates potent in vitro and in vivo activity. J. Saldanha, K. Della Croce, H. Vankayalapati, I. Georgiev, R. Nagle and D. Mahadevan The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724.

Spier CM, LeBlanc M, Chase EM, Fisher RI , Miller TP. Histologic subtypes do not confer unique outcomes in early-stage lymphoma: Long-term followup of SWOG 8736. 46 th American Society of Hematology Annual Meeting, San Diego CA 2004. Accepted for poster presentation (Blood 104: pg 891a, #3263, 2004)

Wiestner A, Chiorazzi M, Lai R, Rosenwald A, Mueller-Hermelink HK, Ott G, et al, Fisher RI, Grogan TM, Miller TP , Wilson WH, Jaffe ES, Staudt LM for the Lymphoma/Leukemia Molecular Profiling Project. High cyclin D1 expression is associated with increased proliferation rate and decreased survival in mantle cell lymphoma (MCL) and is caused by genomic deletions and mutations that enhance mRNA stability. Submitted 46 th American Society of Hematology Annual Meeting, San Diego CA 2004.

Tome ME, Johnson DB, Rimsza LM, Roberts RA, Oberly LW, Grogan TM, Miller TP , Briehl MM. Decreased MnSOD is correlated with poor survival in diffuse large B-cell lymphoma. Presented, 3 rd International Conference on Superoxide Dismutases, Institut Pasteur, Paris , France , June 10-11, 2004

Briehl, MM, Johnson, DB, Tome, ME, Rimsza, LM, Roberts, RA, Grogan, TM, Miller, TP . A redox score based on microarry data identifies lymphoma patients with poor survival. Free Rad Biol Med 37:S170, 2004.

Rimsza LM, Roberts R, Campo E, Grogan TM, Bea S, Salaverria I, Zettl, Fisher R, Unger J, LeBlanc M, Staudt L, Gascoyne R, Chan W, Weisenburger D, Greiner T, Jaffe E, Braziel R, Mueller-Hermelink H, Miller T . Loss of Major Histocompatibility Class II (MHCII) Expression in Nodal Diffuse Large B Cell Lymphoma (DLBCL) Is Highly Coordinated and Unlikely Related to Chromosomal Deletions. Biomedical Research Forum, 2004

Stopeck A, Iannone M, Rimsza LM, Miller T , Fisher R, Bellamy W. Expression of VEGF, VEGF Receptors, and Other Angiogenic Markers in Relapsed Aggressive NHL: Correlative Studies From SWOG S0108 Trial. Presented 46 th American Society of Hematology Annual Meeting, San Diego CA 2004 . Accepted for poster presentation. (Blood 104: 629a, #2288, 2004)

Dave SS, Wright G, Tan B, Rosenwald A, Chan WC, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP , LeBlanc M, Smeland EB, Kvoloy S, Holte H, Delabie J, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Campo E, Montserrat E, Wilson WH, Jaffe ES, Lister A, Davies AJ, Norton AJ, Simon R, Yang L, Powell J, Palma J, Warrington J, Zhao H, Chiorazzi M, Staudt L. LymphDx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma. Presented 46 th American Society of Hematology Annual Meeting, San Diego CA 2004

Maloney DG, Pender-Smith B, Unger JM, Braziel RM, Radich J, Press OW, Miller TP , Grogan TM, LeBlanc M, Fisher RI. FC receptor polymorphisms do no influence progression free survival (PFS) of follicular NHL patients treated with CHOP followed by rituximab (SWOG 9800)., Presented 46 th American Society of Hematology Annual Meeting, San Diego CA 2004 (Blood 104: 170a, #589, 2004)

Miller TP, Unger JM, Spier C, Stea B, Cantu E, LeBlanc M , Fisher RI. Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). Presented 46 th American Society of Hematology Annual Meeting, San Diego CA 2004. Accepted for oral presentation. (Blood104: 48a, #158, 2004)

Mahadevan D, Spier C, Della Croce K, Miller S, George B, Riley C, Warner S, Grogan TM, Miller TP . Gene expression profiling of peripheral T-cell lymphoma (PTCL, NOS) and comparison to diffuse large B-cell lymphoma (DLBCL). Presented 46 th American Society of Hematology Annual Meeting, San Diego CA 2004. Accepted for poster presentation. (Blood 104: 627a, #2277, 2004)

Grogan TM, Miller TP , Fisher RI, Delabie J Kvaloy S, Mueller-Hermelink HK, Moreno V, Montserrat E, Wilson WH, Staudt LM, Rosenwald A, and Campo E for the Leukemia/Lymphoma Molecular Profiling Project. Chromosomal imbalances in germinal center B-cell like and activated B-cell like diffuse large B-cell lymphoma influence gene expression signatures and improve the gene expression-based survival prediction. Blood 104 (11): 122a (#415), 2004

Tome ME, Rimsza LM, Roberts, RA, Brown LW, Grogan TM, Miller TP , Briehl MM. Downregulated antioxidant defense enzyme expression is correlated with poor survival in DLBCL. NIH CA71768 & HHMI #71195-521304, Abstract, ASIP, 2004

Hayes DF, Cristofanilli M, Budd GT, Ellis M, Stopeck A , Matera J, Miller MC, Doyle GV, Allard WJ, Terstappen LW. Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional trial. Proc Am Soc Clin Oncol 23:5, 509, 2004.

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C , Stopeck A , Terstappen LVMM. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant disease. Proc Am Soc Clin Oncol 23:844, 9552, 2004.

Escalante, A.M., Landowski, T.H., Dorr, R.T., and Stratton S.P . Role of NF-?B in UVB-Irradiated Immortalized Human Keratinocytes Post-Treated with Epigallocatechin-3-gallate. Cancer Epidemiol. Biomarkers Prev. 25:1879s, 2004.

A Stopeck , M Iannone, L Rimsza, T Miller , R Fisher, W Bellamy. Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive non-Hodgkin's lymphoma: Correlative studies from the SWOG S0108 trial. Presented at 46 Annual Meeting of American Society of Hematology, December, 2004. Abstract 2288.

Hayes DF, Miller MC, Cristofanilli M, Ellis MJ, Stopeck A , Allard WJ, Matera J, Doyle GV, Terstappen LW, Budd GT. Circulating tumor cells are a reliable predictor of progression free survival and overall survival during therapy of patients with metastatic breast cancer. Presented at the 27th Annual San Antonio Breast Cancer Symposium, December, 2004. Abstract 6015.

Cristofanillli M, Reuben JM, Fritsche HA, Hayes DF, Budd TG, Ellis MJ, Stopeck A , Miller CM, Matera J, Allard JW. Detection of circulating tumor cells (CTCs) is a prognostic factor in first-line metastatic breast cancer (MBC). Presented at the 27th Annual San Antonio Breast Cancer Symposium, December, 2004. Abstract 6016.

Budd GT, Cristofanilli M, Terstappen LW, Ellis MJ, Stopeck A , Allard WJ, Matera J, Miller MC, Doyle GV, Hayes DF. Correlation of changes in circulating tumor cells and radiographic response to treatment in patients with metastatic breast cancer. Presented at the 27th Annual San Antonio Breast Cancer Symposium, December, 2004. Abstract 6018.

(11) Other Publications
(book reviews, commentaries, editorials or other non-refereed scholarly material, etc.)

Kelloff GJ, Schilsky RL, Alberts DS , Day RW, Guyton KZ, Pearce HL, Peck JC, Phillips R, Sigman CC: colorectal adenomas: a prototype for the use of surrogate endpoints in the development of cancer prevention drugs. Clin Cancer Res, Special Review 10:3908-3918, 2004.

Harris RB and Alberts DS : Strategies for skin cancer prevention. Int J Dermatol 43:243-251, 2004.

Alberts DS : Case Review: Stage IIIC ovarian cancer. Case Studies in Oncol. July 2004.

Potter JD, Alberts DS : One year and counting: a status report from John and Dave. Cancer Epidemiol Biomarkers Prev 13:1, 2004.

Jacobs B, Martinez EM, Alberts DS : Response to Dr. Heaney. J Natl Cancer Inst, 96(10):805, 2004.

Alberts DS : Case discussion #1, 2 nd Int Gynecol Cancer Society Tumor Board, International Gynecologic Cancer Society Listserve, 2004.

Dragovich, T . "Emerging Roles of Target-Based Therapies for Gastrointestinal Malignancies" submitted to Journal of B.U. O.N. in December 2004. (Invited Review)

Ebbinghaus SW , Gordon MS. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematol Oncol Clin North Am . 18:1143-59, 2004

Dalton WS, Hazlehurst L, Shain K, Landowski T , Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies, Semin Hematol, 41(2 Suppl 4):1-5 (2004).

Mahadevan D and Garewal H . American College of Physicians-American Board of Internal Medicine PIER Module: Advances in the diagnosis and treatment of Chronic Lymphocytic Leukemia. September 2003.

Miller TP . The Limits of Limited Stage Lymphoma (Editorial). Journal of Clinical Oncology, Editorial, 22:2982-2984, 2004

(29) Presentations
(scholarly presentations and poster sessions not currently published or expected to be published in the future)

Nuclear Chromatin Characteristics of Breast Epithelial Cells Obtained by Ductal Lavage Walling E, DH Frank , PA Thompson, J Davis, D Thompson, PH Bartels, , J Ranger-Moore, C Kim, J Warneke, TE Crane, DS Alberts and C Thomson.

AHSC Frontiers in Biomedical Research Poster Forum, Wednesday, September 15th, 2004 Correlates of Imexon sensitivity in human multiple myeloma cell lines. Betty K. Samulitis, Terry H. Landowski , Robert T. Dorr. submitted, Anti-Cancer Drugs.

Induction of apoptosis and cell cycle arrest by Imexon in human pancreatic cancer cell lines. Robert T. Dorr, Mary Ann Raymond, Terry H. Landowski , Nicholas O. Roman, Shoji Fukushima . in preparation, International Journal of Gastrointestinal Cancer

Fisher RI, Miller TP , et al. Presented 46 th American Society of Hematology Annual Meeting, San Diego CA 2004.

Miller TP . Limited Stage Lymphoma: Treatment for Aggressive Histologies. in Bowdy VC, Berliner N, Larson RA, Leung LL (eds) Hematology 2004. American Society of Hematology, Washington , DC , 2004.

Invited oral presentation : Stratton, S.P . Nordihydroguaiaretic Acid (Actinex®) for Skin Cancer Prevention, 6th Annual Arizona Cancer Drug Symposium: Novel Targets and Mechanisms for New Cancer Drugs, Feb 20, 2004 , Arizona Cancer Center , Tucson , AZ

Invited oral presentation : Stratton, S.P . Chemoprevention of skin cancer , University of New England College of Medicine Seminar Series, August 6, 2004 , Biddeford , ME

Poster presentation : Pourpak, A., Dorr, R.T., Meyers, R.O., Powell, M.B., & Stratton, S.P . Anti-melanoma activity of the bisphosphonate ester APOMINET is independent of Ras farnesylation and apoptotic cell death in human melanoma cell lines . 96 th Annual Meeting, American Association for Cancer Research, Anaheim , CA , April 2005.

Invited oral presentation : Stratton, S.P . Sun Safety and Prevention of Skin Cancer . April 8, 2004 , American Cancer Society, IBM, Tucson , AZ

Invited oral presentation: Stratton, S.P., Alberts, D.S. Challenges in Academic Drug Development: Development of New Drugs for Prevention of Skin Cancer. Arizona Statewide Translational Working Group, November 10, 2004 , TGen, Phoenix, AZ Sanofi Synthelabo Inc. Preceptorship. Chemoprevention . January 9, 2004

Lopez AM , Four Corner's Telemedicine and Telehealth Planning Conference. Telemedicine: Clinical Practice. August 23-24, 2004 , Tucson , AZ.

Lopez AM , University of North Texas Health Sciences Center Centers for Medicare and Medicaid Services. Hispanic Health Services Research Conference - Improving Health Outcomes and Health Disparities: Research and Intervention Perspective . Understanding the Role of Culture in the Access and Utilization of Telemedicine Health Services among Hispanic, Native Americans and White non-Hispanic Populations . May 28, 2004 .

Lopez AM Arizona Telemedicine Association. Training session. March 13-14, 2004 .

Lopez AM HHS Site Visit, UofA National Center of Excellence in Women's Health. Demonstration of Arizona Telemedicine Program. March 2, 2004 , Tucson , AZ.

Lopez AM, University of Arizona , Circle of Hope. Complementary Medicine in Cancer Care . February 17, 2004 . Tucson , AZ

Lopez AM University of Arizona , Arizona Telemedicine Program. Clinical Applications of Telemedicine . February 4, 2004 . Tucson , AZ

Arizona Cancer Center/Sunstone Healing Center. Supportive Care Vision for Arizona : Rural Hispanic Populations October 29-30, 2004 , Tucson , AZ

Lopez AM National Congress on the State of the Science in Nursing Research. Research on Mechanisms for Reducing Cancer-Related Injury. October 7-9, 2004 , Washington , DC .

Lopez AM Southern Arizona Oncology Nurses Society (SAONS). Update on San Antonio Breast Cancer meeting . Presented for AstraZeneca on April 14, 2004 , Phoenix AZ.

Lopez AM Health Services Advisory Group (HSAG) Arizona State Diabetes Collaborative Outcomes Congress. Controversy in Cancer Screening . May 21, 2004 , Phoenix AZ .

Lopez AM 115 th AAMC Annual Meeting. Transforming the Curriculum: The Reproductive Health Initiative Model Curriculum as a Catalyst. November 10, 2004 , Washington , DC .

Lopez AM THMEP (TMC/SEAHEC/Mariposa Community Health Center) 11 th Annual Primary Care Physician Conference. Latest Data on Cancer Prevention October 16-17, 2004 , Rio Rico AZ.

Lopez AM Arizona Medical Association (ArMA). Mammography Momentum Panelist. Breast Health Controversies . April 12, 2004 , Phoenix AZ.

Lopez AM Health Services Advisory Group (HSAG). Hormone Replacement Therapy and Mammography Readings . April 12, 2004 , Flagstaff AZ.

Lopez AM Tucson Hospitals Medical Education Program Inc (THMEP) Grand Rounds. Epidemiology of Breast Cancer . April 28, 2004 , Tucson AZ.

Lopez AM HHA Site Visit, UofA National Center of Excellence in Women's Health. Present at CoE WHRC Clinical Service. March 2, 2004 , Tucson AZ.

Dragovich T , Maricopa County Hospital , Cancer Center , Phoenix , Arizona : "Update on Therapy of Metastatic Colorectal Cancer", April 2004

Dragovich T, Sun Health/St. Joseph's Geriatric Fellowship Program, Sun City , Arizona . "Colorectal Cancer", September 2004.

Dragovich T, AHSC Frontiers in Biomedical Research Poster Forum, University of Arizona, College of Medicine, Tucson, Arizona: "Phase I/II Trial of L-NNP (Aroplatin) in Patients with Metastatic Colorectal Cancer', September, 2004.

Dragovich T, The Southern California Academy of Clinical Oncology (SCACO) 110 th Cancer Seminar, "GI Cancer 2004 Advances in Therapy for Esophagogastric and Pancreatic Cancer", Century City , California , November 30, 2004 .

Webmaster | Privacy Policy | Disclaimer
Arizona Cancer Center :: 1515 North Campbell Ave., Tucson, AZ 85724-5024
Copyright ABOR :: All rights reserved.